---
schema_version: "secwatch.filing_event.v1"
accession: "0000721371-24-000026"
form_type: "8-K"
ticker: "CAH"
cik: "0000721371"
company_name: "CARDINAL HEALTH INC"
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T14:49:03.828450+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cardinal Health OptumRx contracts not renewed; reaffirms FY2024 non-GAAP EPS guidance $7.20-$7.35

## Summary
- OptumRx contracts expire June 2024; not renewed; 16% of FY2023 consolidated revenue.
- About 90% of these sales were non-specialty bulk shipments with meaningfully lower operating margin.
- Reiterates long-term segment profit CAGR 4-6% and non-GAAP EPS CAGR 12-14% (FY2024-2026 vs FY2023).
- Expects FY2025 growth in Pharmaceutical & Specialty segment profit and non-GAAP EPS, partially offsetting impact.
- Adjusted free cash flow target ~$2B average FY2024-2026, but lower in FY2025 due to working capital unwinding.

## SEC filing metadata
- accession: 0000721371-24-000026
- form_type: 8-K
- ticker: CAH
- cik: 0000721371
- company_name: CARDINAL HEALTH INC
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/721371/000072137124000026/0000721371-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/721371/000072137124000026/cah-20240422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000721371-24-000026
- JSON: https://secwatch.observer/filing/0000721371-24-000026.json
- Plain text: https://secwatch.observer/filing/0000721371-24-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.